[Pembrolizumab as first-line therapy in microsatellite instability metastatic colorectal cancers]. 2021

Dimitri Pureur, and Manuel Rodrigues, and Anthony Turpin
Centre hospitalier régional universitaire de Besançon, service de gastro-entérologie et de nutrition, 25000 Besançon, France. Electronic address: pureur.dimitri@hotmail.fr.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000074322 Antineoplastic Agents, Immunological Antineoplastic agents containing immunological agents (e.g. MAbs). These pharmacologic preparations inhibit or prevent the proliferation of NEOPLASMS. Antineoplastic MAbs,Antineoplastics, Monoclonal Antibodies,Antineoplastics, Monoclonal Antibody,MAbs, Antineoplastic,Monoclonal Antibodies, Antineoplastic,Antibodies Antineoplastics, Monoclonal,Antineoplastic Monoclonal Antibodies,Immunological Antineoplastic Agents,Monoclonal Antibodies Antineoplastics,Monoclonal Antibody Antineoplastics
D015179 Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. Colorectal Cancer,Colorectal Carcinoma,Colorectal Tumors,Neoplasms, Colorectal,Cancer, Colorectal,Cancers, Colorectal,Carcinoma, Colorectal,Carcinomas, Colorectal,Colorectal Cancers,Colorectal Carcinomas,Colorectal Neoplasm,Colorectal Tumor,Neoplasm, Colorectal,Tumor, Colorectal,Tumors, Colorectal
D016032 Randomized Controlled Trials as Topic Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical
D017326 Clinical Trials, Phase III as Topic Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries. Clinical Trials, Phase 3 as Topic,Drug Evaluation, FDA Phase 3 as Topic,Drug Evaluation, FDA Phase III as Topic,Evaluation Studies, FDA Phase 3 as Topic,Evaluation Studies, FDA Phase III as Topic
D053842 Microsatellite Instability The occurrence of highly polymorphic mono- and dinucleotide MICROSATELLITE REPEATS in somatic cells. It is a form of genome instability associated with defects in DNA MISMATCH REPAIR. Replication Error Phenotype,Error Phenotype, Replication,Error Phenotypes, Replication,Instability, Microsatellite,Phenotype, Replication Error,Phenotypes, Replication Error,Replication Error Phenotypes
D061067 Antibodies, Monoclonal, Humanized Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab. Antibodies, Humanized,Humanized Antibodies

Related Publications

Dimitri Pureur, and Manuel Rodrigues, and Anthony Turpin
June 1995, International journal of cancer,
Dimitri Pureur, and Manuel Rodrigues, and Anthony Turpin
May 2021, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi,
Dimitri Pureur, and Manuel Rodrigues, and Anthony Turpin
December 2020, The New England journal of medicine,
Dimitri Pureur, and Manuel Rodrigues, and Anthony Turpin
September 2020, European journal of hospital pharmacy : science and practice,
Dimitri Pureur, and Manuel Rodrigues, and Anthony Turpin
March 2023, Annals of palliative medicine,
Dimitri Pureur, and Manuel Rodrigues, and Anthony Turpin
February 2018, Immunotherapy,
Dimitri Pureur, and Manuel Rodrigues, and Anthony Turpin
February 2019, Bulletin du cancer,
Dimitri Pureur, and Manuel Rodrigues, and Anthony Turpin
July 2019, Cancer immunology, immunotherapy : CII,
Dimitri Pureur, and Manuel Rodrigues, and Anthony Turpin
September 2018, Neoplasia (New York, N.Y.),
Copied contents to your clipboard!